Stockscreener 앱 받기
0.00
100.00%
-0.5266
전일 마감가:
$0.5266
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$1.56M
수익:
-
순이익/손실:
$-39.48M
주가수익비율:
0.00
EPS:
-0.76
순현금흐름:
$-32.16M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$13.14
Oncternal Therapeutics Inc Stock (ONCT) Company Profile
명칭
Oncternal Therapeutics Inc
전화
(858) 434-1113
주소
12230 EL CAMINO REAL, SAN DIEGO, CA
ONCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCT
Oncternal Therapeutics Inc
|
0.00 | 1.56M | 0 | -39.48M | -32.16M | -13.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oncternal Therapeutics Inc Stock (ONCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-07 | 개시 | Oppenheimer | Outperform |
| 2021-02-23 | 개시 | Northland Capital | Outperform |
Oncternal Therapeutics Inc 주식(ONCT)의 최신 뉴스
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com - Defense World
Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Marketscreener.com
CELUCelularity Inc. Latest Stock News & Market Updates - StockTitan
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com - Defense World
ONCT stock touches 52-week low at $0.61 amid market challenges - Investing.com Australia
ONCT stock touches 52-week low at $0.61 amid market challenges By Investing.com - Investing.com South Africa
StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
ONCT stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
ONCT stock touches 52-week low at $0.83 amid market challenges - Investing.com
Oncternal shares to be delisted from Nasdaq - Investing.com
Oncternal Therapeutics Reports Q3 2024 Earnings - TipRanks
ONCT (Oncternal Therapeutics) 9-Day RSI : 33.20 (As of Nov. 20, 2024) - GuruFocus.com
Oncternal announces workforce reduction, executive changes - Investing.com
Oncternal Therapeutics to Cut Most of Its Workforce - MarketWatch
Oncternal Therapeutics Announces Workforce Reduction and Executive Changes - TipRanks
ONCT Stock Touches 52-Week Low at $1.03 Amid Market Challenges - Investing.com
Phase 1/2 trial of ONCT-534 in mCRPC has been terminated - Urology Times
Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - Marketscreener.com
Oncternal reports positive prostate cancer treatment results By Investing.com - Investing.com Australia
Oncternal reports positive prostate cancer treatment results - Investing.com India
Oncternal Therapeutics Announces Updated Safety and - GlobeNewswire
B-Cell Non-Hodgkin Lymphoma Pipeline Assessment 2024: Therapies, Clinical Trials, and Growth Prospects | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus - Barchart
ONCT Stock Touches 52-Week Low at $1.19 Amid Market Challenges - Investing.com Australia
Oncternal Therapeutics Inc (ONCT) Q2 2024 Earnings Call Highlights: Advancements in Clinical ... - Yahoo Finance Australia
Oncternal stock jumps 9% on FDA fast track designation - MSN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.58% - MSN
ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges - Investing.com Australia
ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges By Investing.com - Investing.com South Africa
Recent Research Analysts’ Ratings Changes for Oncternal Therapeutics (ONCT) - Defense World
Omnicell Appoints Nnamdi Njoku as New COO - TipRanks
Oncolytics Biotech (TSE:ONC) Reaches New 12-Month Low at $1.20 - Defense World
ONON’s Stock Market Adventure: 85.15% YTD Growth Amidst Volatility - The InvestChronicle
Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer - Silicon UK
ONMD’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Levi & Korsinsky Notifies Shareholders of Outset Medical, - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc.OM - PR Newswire
Fred Alger Management LLC Has $44.73 Million Position in On Holding AG (NYSE:ONON) - MarketBeat
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
Recent Insider Activity Suggests Potential Gains for Outset Medical Inc (OM) - Knox Daily
On Holding's Options Frenzy: What You Need to Know - Benzinga
This Option Provides Gains By Coasting With On Running Shoes - Investor's Business Daily
ONON’s valuation metrics: A comprehensive analysis - US Post News
OM Stock on the Rise: A Promising Investment - The InvestChronicle
Was Outset Medical Inc (OM)’s session last reading good? - US Post News
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows - Baystreet.ca
Views of Wall Street’s Leading Experts on Onconetix Inc - SETE News
Financial Metrics Unveiled: Outset Medical Inc (OM)’s Key Ratios in the Spotlight - The Dwinnex
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World
Outset Medical (OM) Shares Down 94% Since Disclosing FDA - GlobeNewswire
On Holding Options Trading: A Deep Dive into Market Sentiment - Benzinga
ON (NYSE:ONON) Rating Increased to Neutral at Bank of America - MarketBeat
Oncternal Therapeutics Inc (ONCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):